Advertisement

Latest Articles in lupin

Drugmaker Lupin's Profit Halves As US Sales Slump

Indian drugmaker Lupin reported its quarterly net profit nearly halved from a year ago, falling far short of analysts' expectations, as sales at its top market the United States slumped while the company's costs jumped

Read More

Lupin To Introduce Second Generation Antihistamine Tablets In India

The current market for plain antihistamines is estimated to be around Rs 860 crore growing at 14 percent during March 2017, according to IMS MAT.

Read More

NPPA Issues Show Cause Notice To Cadila, Lupin, Abbott Healthcare Among Others

Country’s top drugmakers including Abbott Healthcare, Mankind Pharma, Cadila, Lupin and Biocon are under scanner. NPPA has found around 200 'new drugs' which are either being sold by drug makers without applying for price approvals or have been tweaked to escape the provisions under DPCO

Read More

Vinita Gupta: Always On The Move

Vinita knew exactly what she wanted to do when she joined Lupin. To take IT global and enter the largest, most advanced, and regulated pharma market, the US

Read More

Lupin Q3 Profit Up 21%, Beats Estimate

Lupin Ltd reported a 21 per cent jump in its quarterly profit, beating analysts' estimates, helped by higher sales of its diabetes products in the United States

Read More

Lupin, Eli Lilly Expand Partnership In India

Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import

Read More

Lupin Gets US Nod To Market Tablets Used For Treatment Of HIV Virus

According to a company statement, tentative approval was received for Abacavir Sulfate and Lamivudine tablets

Read More

Lupin Q2 Profit Lags As Costs Rise

Lupin, the world's seventh-largest generic drugmaker, said North America sales rose 73.1 percent to about 20 billion rupees

Read More

Lupin Quarterly Profit Gets Boost From Lower Tax Rate

Sales in North America, Lupin's largest market, surged 82.3 per cent, helped by sales of products bought via the acquisition of Gavis in July, and higher sales of its generic version of diabetes drug Glumetza

Read More

Lupin Buys 21 Generic Brands From Shionogi In Japanese Market

Under the terms of this agreement, Kyowa will book the sales of the 21 products after December 1, 2016, and Shionogi will receive 15.4 billion yen from Kyowa

Read More

Lupin To Buy 21 Branded Drugs From Japan's Shionogi

The portfolio will be transferred to Lupin on Dec. 31, subject to regulatory approvals and certain closing conditions, the companies said

Read More

Market Consolidates As Sensex Creeps Up, Lupin Leads

Market remained in a phase of consolidation as the Sensex edged up 35 points in choppy trade on Thursday ahead of start of earnings season next week and Monsoon session of Parliament amid a higher opening in Europe

Read More

Lupin Says It Sees No Supply Disruption At Plant Despite FDA Observations

The company said it did not expect any disruption to supply from its main manufacturing plant despite what it called minor observations made by the US Food and Drug Administration after an audit

Read More